

Manel Juan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3862793/publications.pdf>

Version: 2024-02-01

160
papers

8,783
citations

70961

41
h-index

46693

89
g-index

174
all docs

174
docs citations

174
times ranked

14607
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies. <i>Journal of the National Cancer Institute</i> , 2022, 114, 436-445.	3.0	29
2	A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. <i>Molecular Therapy</i> , 2022, 30, 550-563.	3.7	21
3	Atypical lymphoid cells circulating in blood in COVID-19 infection: morphology, immunophenotype and prognosis value. <i>Journal of Clinical Pathology</i> , 2022, 75, 104-111.	1.0	14
4	The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001. <i>Bone Marrow Transplantation</i> , 2022, 57, 156-159.	1.3	18
5	Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation. <i>Frontiers in Oncology</i> , 2022, 12, 828471.	1.3	19
6	SARS-CoV-2 T-cell response in COVID-19 convalescent patients with and without lung sequelae. <i>ERJ Open Research</i> , 2022, 8, 00706-2021.	1.1	1
7	Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers. <i>Cancer Immunology Research</i> , 2022, 10, 498-511.	1.6	12
8	Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions. <i>Biomedicines</i> , 2022, 10, 537.	1.4	9
9	Abstract P2-14-13: Talimogene laherparepvec (T-VEC) + atezolizumab combination in early breast cancer (SOLTI-1503 PROMETEO): Safety and efficacy interim analysis. <i>Cancer Research</i> , 2022, 82, P2-14-13-P2-14-13.	0.4	1
10	Immunology in COVID-19; more than diagnosis of infection or the basis of vaccination. <i>Medicina Clínica (English Edition)</i> , 2022, 158, 324-324.	0.1	0
11	Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease. <i>American Journal of Hematology</i> , 2022, 97, 731-739.	2.0	6
12	CD34+CD19 ^{hi} CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. <i>Blood</i> , 2022, 140, 38-44.	0.6	20
13	Physiological lentiviral vectors for the generation of improved CAR-T cells. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 335-349.	2.0	4
14	Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 376-386.	1.3	11
15	CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. <i>Molecular Therapy</i> , 2021, 29, 636-644.	3.7	80
16	Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1026.	1.8	31
17	CAR T cells targeting options in the fight against multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 37-45.	0.2	2
18	Enforced sialylation (sLeX) display in E-selectin ligands by exofucosylation is dispensable for CD19-CAR T cell activity and bone marrow homing. <i>Clinical and Translational Medicine</i> , 2021, 11, e280.	1.7	11

#	ARTICLE	IF	CITATIONS
19	Similarities and differences between the immunopathogenesis of COVID-19-related pediatric multisystem inflammatory syndrome and Kawasaki disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	95
20	Autoimmune biomarkers in porto-ésinusoidal vascular disease: Potential role in its diagnosis and pathophysiology. <i>Liver International</i> , 2021, 41, 2171-2178.	1.9	7
21	NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness. , 2021, 9, e002866.		21
22	Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 3971-3979.	2.6	85
23	Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 2727-2739.	2.6	197
24	CD137 Costimulation Counteracts TGF ^β 2 Inhibition of NK-cell Antitumor Function. <i>Cancer Immunology Research</i> , 2021, 9, 1476-1490.	1.6	15
25	CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?. <i>Cancers</i> , 2021, 13, 4664.	1.7	10
26	Is Hospital Exemption an Alternative or a Bridge to European Medicines Agency for Developing Academic Chimeric Antigen Receptor T-Cell in Europe? Our Experience with ARI-0001. <i>Human Gene Therapy</i> , 2021, 32, 1004-1007.	1.4	16
27	Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches.. <i>Allergologia Et Immunopathologia</i> , 2021, 49, 118-127.	1.0	8
28	The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers. <i>Cancers</i> , 2021, 13, 5418.	1.7	7
29	Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 2837-2837.	0.6	8
30	Design and <i>in Vitro</i> Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4799-4799.	0.6	0
31	Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2021, 138, 552-552.	0.6	2
32	Inmunología en COVID-19; mucho más allá del diagnóstico de la infección o de la vacunación. <i>Medicina Clínica</i> , 2021, 158, 324-324.	0.3	1
33	CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome. <i>Blood</i> , 2021, 138, 735-735.	0.6	7
34	First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma. , 2021, 9, e003783.		17
35	Factors associated with the clinical outcome of patients with relapsed/refractory CD19 ⁺ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. , 2021, 9, e003644.		11
36	Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 100-114.	3.3	31

#	ARTICLE	IF	CITATIONS
37	CART manufacturing process and reasons for academy-pharma collaboration. Immunology Letters, 2020, 217, 39-48.	1.1	9
38	Purification, Culture, and CD19-CAR Lentiviral Transduction of Adult and Umbilical Cord Blood NK Cells. Current Protocols in Immunology, 2020, 131, e108.	3.6	10
39	Severe Autoinflammatory Manifestations and Antibody Deficiency Due to Novel Hypermorphic PLCG2 Mutations. Journal of Clinical Immunology, 2020, 40, 987-1000.	2.0	41
40	Cell Banking of HEK293T cell line for clinical-grade lentiviral particles manufacturing. Translational Medicine Communications, 2020, 5, .	0.5	1
41	Manufacturing and Management of CAR T-Cell Therapy in COVID-19's Time: Central Versus Point of Care Proposals. Frontiers in Immunology, 2020, 11, 573179.	2.2	12
42	Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity. , 2020, 8, e001419.		16
43	109P Subpopulations of peripheral blood lymphocytes and response to immunotherapy across cancer-types. Annals of Oncology, 2020, 31, S284-S285.	0.6	0
44	Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. Haematologica, 2020, 106, 173-184.	1.7	25
45	Single-cycle rituximab-induced immunologic changes in children. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	13
46	Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial. Frontiers in Immunology, 2020, 11, 482.	2.2	77
47	SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. Future Oncology, 2020, 16, 1801-1813.	1.1	8
48	41P A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (REO-027, AWARE-1). Annals of Oncology, 2020, 31, S30.	0.6	1
49	CAR-T immunotherapy in paediatric haemato-oncology: present and future. Anales De PediatrÃa (English Edition), 2020, 93, 1-3.	0.1	0
50	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. Cells, 2020, 9, 203.	1.8	15
51	Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck. World Journal of Clinical Oncology, 2020, 11, 898-917.	0.9	4
52	Abstract OT1-01-01: SOLTI-1503 PROMETEO: Combination of talimogene laherparepvec (T-VEC) with atezolizumab in patients with residual breast cancer after standard neoadjuvant multi-agent chemotherapy. Cancer Research, 2020, 80, OT1-01-01-OT1-01-01.	0.4	4
53	806...Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer. , 2020, , .		0
54	Multi-level immune response network in mild-moderate Chronic Obstructive Pulmonary Disease (COPD). Respiratory Research, 2019, 20, 152.	1.4	34

#	ARTICLE	IF	CITATIONS
55	Primary and Secondary Immunodeficiency Diseases in Oncohaematology: Warning Signs, Diagnosis, and Management. <i>Frontiers in Immunology</i> , 2019, 10, 586.	2.2	40
56	Next-generation HLA typing of 382 International Histocompatibility Working Group reference B-lymphoblastoid cell lines: Report from the 17th International HLA and Immunogenetics Workshop. <i>Human Immunology</i> , 2019, 80, 449-460.	1.2	20
57	Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 8463-8470.	3.3	112
58	Toll-like receptor 3 deficiency in autoimmune encephalitis post-herpes simplex encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e611.	3.1	18
59	Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2019, 3, e174.	1.2	5
60	Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. <i>Scientific Reports</i> , 2019, 9, 18729.	1.6	74
61	Global Proteomic and Methylome Analysis in Human Induced Pluripotent Stem Cells Reveals Overexpression of a Human TLR3 Affecting Proper Innate Immune Response Signaling. <i>Stem Cells</i> , 2019, 37, 476-488.	1.4	7
62	Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 12, 134-144.	1.8	77
63	ARV7 and ARFL mRNA in blood to predict androgen receptor inhibitors and docetaxel response in castration-resistant prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 207-207.	0.8	0
64	Laboratory evaluation of the IFN- β circuit for the molecular diagnosis of Mendelian susceptibility to mycobacterial disease. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 184-204.	2.7	43
65	Sirolimus as an alternative treatment in patients with granulomatous lymphocytic lung disease and humoral immunodeficiency with impaired regulatory T cells. <i>Pediatric Allergy and Immunology</i> , 2018, 29, 425-432.	1.1	30
66	Detection of inflammatory monocytes but not mesenchymal stem/stromal cells in peripheral blood of patients with myelofibrosis. <i>British Journal of Haematology</i> , 2018, 181, 133-137.	1.2	7
67	CAR-T cell therapy, a door is open to find innumerable possibilities of treatments for cancer patients. <i>Turkish Journal of Haematology</i> , 2018, 35, 217-228.	0.2	9
68	DIPG-18. IMMUNE RESPONSE GENERATED WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIPG. <i>Neuro-Oncology</i> , 2018, 20, i52-i52.	0.6	0
69	Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. <i>Lancet Neurology</i> , The, 2018, 17, 760-772.	4.9	422
70	B Regulatory Cells: Players in Pregnancy and Early Life. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2099.	1.8	31
71	Severe BCG-osis Misdiagnosed as Multidrug-Resistant Tuberculosis in an IL-12 β -Deficient Peruvian Girl. <i>Journal of Clinical Immunology</i> , 2018, 38, 712-716.	2.0	8
72	Evaluating the Genetics of Common Variable Immunodeficiency: Monogenetic Model and Beyond. <i>Frontiers in Immunology</i> , 2018, 9, 636.	2.2	142

#	ARTICLE	IF	CITATIONS
73	Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Oncology</i> , 2018, 8, 127.	1.3	31
74	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. <i>Annals of Oncology</i> , 2018, 29, 2121-2128.	0.6	74
75	Abstract LB-083: Targeting IRAK4 disrupts inflammatory pathways and tumor microenvironment in chronic lymphocytic leukemia regardless MYD88 mutational status. , 2018, , .		0
76	Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 2650-2650.	0.6	0
77	DNA demethylation of inflammasome-associated genes is enhanced in patients with cryopyrin-associated periodic syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 202-211.e6.	1.5	57
78	Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes. <i>Stem Cell Reports</i> , 2017, 8, 1573-1586.	2.3	73
79	Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20 treatment in renal pathology. <i>Immunobiology</i> , 2017, 222, 620-630.	0.8	15
80	Evans Syndrome as First Manifestation of Primary Immunodeficiency in Clinical Practice. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, 490-494.	0.3	11
81	Elimination of Anti-HLA Alloantibody Producing B Cells through the Use of a CAR-Like HLA Molecule in T Cells. <i>Transplantation</i> , 2017, 101, S17.	0.5	0
82	mTOR intersects antibody-inducing signals from TACI in marginal zone B cells. <i>Nature Communications</i> , 2017, 8, 1462.	5.8	65
83	DIPG-08. PHASE IB IMMUNOTHERAPY CLINICAL TRIAL WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). <i>Neuro-Oncology</i> , 2017, 19, iv6-iv6.	0.6	0
84	Characterization of the Highly Prevalent Regulatory CD24 ^{hi} CD38 ^{hi} B-Cell Population in Human Cord Blood. <i>Frontiers in Immunology</i> , 2017, 8, 201.	2.2	19
85	Immunological Changes in Blood of Newborns Exposed to Anti-TNF- α during Pregnancy. <i>Frontiers in Immunology</i> , 2017, 8, 1123.	2.2	51
86	Pulmonary and systemic cellular immune response network in patients with mild-moderate COPD. , 2017, , .		0
87	Clues to management of neonatally diagnosed <sc>BTK</sc> deficiency. <i>Pediatric Allergy and Immunology</i> , 2016, 27, 428-430.	1.1	0
88	Nonsteroidal anti-inflammatory drugs enhance IgE-mediated activation of human basophils in patients with food anaphylaxis dependent on and independent of nonsteroidal anti-inflammatory drugs. <i>Clinical and Experimental Allergy</i> , 2016, 46, 1111-1119.	1.4	26
89	The inflammasome pathway in stable COPD and acute exacerbations. <i>ERJ Open Research</i> , 2016, 2, 00002-2016.	1.1	47
90	Humoral deficiency in three paediatric patients with genetic diseases. <i>Allergologia Et Immunopathologia</i> , 2016, 44, 257-262.	1.0	5

#	ARTICLE	IF	CITATIONS
91	Immunophenotypic analysis and quantification of B-1 and B-2 B cells during human fetal hematopoietic development. <i>Leukemia</i> , 2016, 30, 1603-1606.	3.3	18
92	Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon. <i>PLoS ONE</i> , 2016, 11, e0166631.	1.1	5
93	From Primary Immunodeficiency to Autoimmunity: How Extreme Situations Highlight the Main Genetic Factors Involved in Autoimmune Disease. <i>MOJ Immunology</i> , 2016, 4, .	11.0	7
94	Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: A TCGA pan-cancer analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3033-3033.	0.8	0
95	Association of Polymorphisms in IRAK1, IRAK4 and MyD88, and Severe Invasive Pneumococcal Disease. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 1008-1013.	1.1	16
96	Jug r 2â€“reactive CD4+ T cells have a dominant immune role in walnut allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 983-992.e7.	1.5	25
97	Neutrophil function in patients with chronic hepatitis C (CHC) undergoing triple antiviral therapy (TT) with first and second generation protease inhibitors (PI). <i>Digestive and Liver Disease</i> , 2015, 47, e37.	0.4	0
98	Non-Hodgkin lymphoma in pediatric patients with common variable immunodeficiency. <i>European Journal of Pediatrics</i> , 2015, 174, 1069-1076.	1.3	23
99	Mutations in the Toll-like receptor/MYD88 pathway in young (â‰¥50 years) CLL patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S203.	0.2	0
100	Characterization of TCR repertoire of CD4+ and CD8+ T cells from patients with multiple myeloma in sustained complete remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e226-e227.	0.2	0
101	Recurrent Invasive Pneumococcal Disease in Children: Underlying Clinical Conditions, and Immunological and Microbiological Characteristics. <i>PLoS ONE</i> , 2015, 10, e0118848.	1.1	12
102	Long-Term Survivors after Stem Cell Transplantation in Multiple Myeloma: Bone Marrow Minimal Residual Disease, PET/CT and Immunological Status. <i>Blood</i> , 2015, 126, 4192-4192.	0.6	0
103	Pathogenic Mechanisms and Clinical Relevance of Autoantibodies. , 2014, , 51-57.		0
104	Novel and atypical splicing mutation in a compound heterozygous UNC13D defect presenting in Familial Hemophagocytic Lymphohistiocytosis triggered by EBV infection. <i>Clinical Immunology</i> , 2014, 153, 292-297.	1.4	6
105	Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells. <i>Nature Immunology</i> , 2014, 15, 354-364.	7.0	249
106	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. <i>Blood</i> , 2014, 123, 3790-3796.	0.6	97
107	Serum allergenâ€“specific <scp>I</scp><scp>A</scp> is not associated with natural or induced tolerance to egg in children. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 1327-1332.	2.7	18
108	Massively parallel sequencing reveals maternal somatic IL2RG mosaicism in an X-linked severe combined immunodeficiency family. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 741-743.e2.	1.5	10

#	ARTICLE	IF	CITATIONS
109	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18250-18255.	3.3	488
110	Lipid transfer protein syndrome: clinical pattern, cofactor effect and profile of molecular sensitization to plantâ€œfoods and pollens. Clinical and Experimental Allergy, 2012, 42, 1529-1539.	1.4	154
111	InmunologÃa y los Premios Nobel 2011. Inmunologia (Barcelona, Spain: 1987), 2012, 31, 1-3.	0.1	1
112	B cellâ€œhelper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nature Immunology, 2012, 13, 170-180.	7.0	615
113	Type I leucocyte adhesion deficiency (LAD I). Report of a case. Allergologia Et Immunopathologia, 2012, 40, 254-258.	1.0	1
114	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature, 2011, 475, 101-105.	13.7	1,364
115	Otro signo de identidad de nuestra sociedad: GECLID-SEI. Inmunologia (Barcelona, Spain: 1987), 2011, 30, 77-78.	0.1	0
116	LTBP2 and CYP1B1 mutations and associated ocular phenotypes in the Roma/Gypsy founder population. European Journal of Human Genetics, 2011, 19, 326-333.	1.4	60
117	A SNP in intron 1 of TSHR controls its thymic expression and susceptibility to Gravesâ€™ disease suggesting central tolerance failure in pathogenesis. Journal of Translational Medicine, 2011, 9, .	1.8	0
118	Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2011, 52, 2064-2068.	0.6	16
119	Association of an SNP with intrathymic transcription of TSHR and Graves' disease: a role for defective thymic tolerance. Human Molecular Genetics, 2011, 20, 3415-3423.	1.4	74
120	CCL4L Polymorphisms and CCL4/CCL4L Serum Levels Are Associated with Psoriasis Severity. Journal of Investigative Dermatology, 2011, 131, 1830-1837.	0.3	25
121	Reassessing the role of HLAâ€œDRB3 Tâ€œcell responses: Evidence for significant expression and complementary antigen presentation. European Journal of Immunology, 2010, 40, 91-102.	1.6	21
122	A somatic <i>NLRP3</i> mutation as a cause of a sporadic case of chronic infantile neurologic, cutaneous, articular syndrome/neonatalâ€œonset multisystem inflammatory disease: Novel evidence of the role of lowâ€œlevel mosaicism as the pathophysiologic mechanism underlying mendelian inherited diseases. Arthritis and Rheumatism, 2010, 62, 1158-1166.	6.7	71
123	Copy number variation in chemokine superfamily: the complex scene of<i>CCL3L</i>â€œ<i>CCL4L</i>genes in health and disease. Clinical and Experimental Immunology, 2010, 162, 41-52.	1.1	36
124	Immune Status In Patients with Chronic Lymphocytic Leukemia and Sustained Complete Remission: A Multiparametric Analysis. Blood, 2010, 116, 1389-1389.	0.6	0
125	Copy number variation in the CCL4L gene is associated with susceptibility to acute rejection in lung transplantation. Genes and Immunity, 2009, 10, 254-259.	2.2	24
126	Pyogenic Bacterial Infections in Humans with MyD88 Deficiency. Science, 2008, 321, 691-696.	6.0	844

#	ARTICLE	IF	CITATIONS
127	HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4. <i>Retrovirology</i> , 2008, 5, 32.	0.9	46
128	Common variants in NLRP2 and NLRP3 genes are strong prognostic factors for the outcome of HLA-identical sibling allogeneic stem cell transplantation. <i>Blood</i> , 2008, 112, 4337-4342.	0.6	34
129	Population structure in copy number variation and SNPs in the CCL4L chemokine gene. <i>Genes and Immunity</i> , 2008, 9, 279-288.	2.2	19
130	Mapping of Helper Epitopes to HPA-1a in Neonatal Alloimmune Thrombocytopenia with T-Cell Clones. <i>Blood</i> , 2008, 112, 3040-3040.	0.6	4
131	The chemokine network. I. How the genomic organization of chemokines contains clues for deciphering their functional complexity. <i>Clinical and Experimental Immunology</i> , 2007, 148, 208-217.	1.1	85
132	The chemokine network. II. On how polymorphisms and alternative splicing increase the number of molecular species and configure intricate patterns of disease susceptibility. <i>Clinical and Experimental Immunology</i> , 2007, 150, 1-12.	1.1	55
133	One-tube-PCR technique for CCL2, CCL3, CCL4 and CCL5 applied to fine needle aspiration biopsies shows different profiles in autoimmune and non-autoimmune thyroid disorders. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 342-349.	1.8	9
134	Real-Time PCR Using Fluorescent Resonance Emission Transfer Probes for HLA-B Typing. <i>Human Immunology</i> , 2006, 67, 374-385.	1.2	10
135	Multiple Products Derived from Two CCL4 Loci: High Incidence of a New Polymorphism in HIV+ Patients. <i>Journal of Immunology</i> , 2005, 174, 5655-5664.	0.4	45
136	Insulin alleles and autoimmune regulator (AIRE) gene expression both influence insulin expression in the thymus. <i>Journal of Autoimmunity</i> , 2005, 25, 312-318.	3.0	50
137	Development of a new HLA-DRB real-time PCR typing method. <i>Human Immunology</i> , 2005, 66, 85-91.	1.2	14
138	HLA-B27 genotyping by Fluorescent Resonance Emission Transfer (FRET) probes in real-time PCR. <i>Human Immunology</i> , 2004, 65, 826-838.	1.2	22
139	Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. <i>Aids</i> , 2004, 18, 459-463.	1.0	103
140	Frequency of Antineutrophil Cytoplasmic Antibody in Graves' Disease Patients Treated with Methimazole. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2141-2146.	1.8	44
141	Chemokines Determine Local Lymphoneogenesis and a Reduction of Circulating CXCR4+ T and CCR7 B and T Lymphocytes in Thyroid Autoimmune Diseases. <i>Journal of Immunology</i> , 2003, 170, 6320-6328.	0.4	100
142	ANCA antibodies in Graves' disease. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 90-91.	0.5	13
143	Thyroid Autoimmune Disease. <i>American Journal of Pathology</i> , 2001, 159, 861-873.	1.9	261
144	Expression of the Human Glucocorticoid Receptor $\hat{1}\alpha$ and $\hat{1}\beta$ Isoforms in Human Respiratory Epithelial Cells and Their Regulation by Dexamethasone. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001, 24, 49-57.	1.4	104

#	ARTICLE	IF	CITATIONS
145	Fibronectin Upregulates Gelatinase B (MMP-9) and Induces Coordinated Expression of Gelatinase A (MMP-2) and Its Activator MT1-MMP (MMP-14) by Human T Lymphocyte Cell Lines. A Process Repressed Through RAS/MAP Kinase Signaling Pathways. <i>Blood</i> , 1999, 94, 2754-2766.	0.6	177
146	Efficacy of Low-dose Subcutaneous Interleukin-2 to Treat Advanced Human Immunodeficiency Virus Type 1 in Persons with $\geq 1/4$ CD4 T Cells and Undetectable Plasma Virus Load. <i>Journal of Infectious Diseases</i> , 1999, 180, 56-60.	1.9	110
147	Cyclooxygenase-2 mRNA Is Downexpressed in Nasal Polyps from Aspirin-sensitive Asthmatics. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 291-296.	2.5	206
148	Regulation of ICAM-3 and other adhesion molecule expressions on eosinophils in vitro. Effects of dexamethasone. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1999, 54, 1293-1298.	2.7	19
149	Estradiol enhances endothelial cell interactions with extracellular matrix proteins via an increase in integrin expression and function. <i>Angiogenesis</i> , 1999, 3, 271-280.	3.7	34
150	Isolation of two CD50 (ICAM-3)-negative Jurkat T cell clones and their application for analysis of CD50 function. <i>Tissue Antigens</i> , 1998, 51, 509-519.	1.0	1
151	Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. <i>Arthritis and Rheumatism</i> , 1998, 41, 435-444.	6.7	56
152	Expression of intercellular adhesion molecule-3 (ICAM-3/CD50) in malignant lymphoproliferative disorders and solid tumors. <i>Tissue Antigens</i> , 1996, 48, 271-277.	1.0	9
153	Stimulation through CD50 (ICAM-3) induces both activation and programmed cell death of human thymocytes. <i>Tissue Antigens</i> , 1996, 48, 626-635.	1.0	16
154	CD50 (intercellular adhesion molecule-3) is expressed at higher levels on memory than on naive human T cells but induces a similar calcium mobilization on both subsets. <i>Tissue Antigens</i> , 1995, 46, 32-44.	1.0	14
155	CD50 (intercellular adhesion molecule 3) stimulation induces calcium mobilization and tyrosine phosphorylation through p59fyn and p56lck in Jurkat T cell line. <i>Journal of Experimental Medicine</i> , 1994, 179, 1747-1756.	4.2	60
156	Prognostic significance of the loss of heterozygosity of nm23-h1 and p53 genes in human colorectal carcinomas. <i>Cancer</i> , 1994, 73, 2913-2921.	2.0	65
157	Signaling through CD50 (ICAM-3) stimulates T lymphocyte binding to human umbilical vein endothelial cells and extracellular matrix proteins via an increase in $\beta 1$ and $\beta 2$ integrin function. <i>European Journal of Immunology</i> , 1994, 24, 1377-1382.	1.6	50
158	CDw50 and ICAM-3: Two names for the same molecule. <i>European Journal of Immunology</i> , 1993, 23, 1508-1512.	1.6	34
159	Rsa polymorphism of the human CD27 gene, a member of nerve growth factor receptor gene family. <i>Human Molecular Genetics</i> , 1992, 1, 660-660.	1.4	1
160	CoVITEST: A Fast and Reliable Method to Monitor Anti-SARS-CoV-2 Specific T Cells From Whole Blood. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2